The Coagulation System as a Target for the Treatment of Human Gliomas

Deborah L. Ornstein; Kenneth R. Meehan; Leo R. Zacharski

doi:10.1055/s-2002-20561

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2002; 28(1): 19-28
DOI: 10.1055/s-2002-20561

The Coagulation System as a Target for the Treatment of Human Gliomas

Deborah L. Ornstein¹ , Kenneth R. Meehan² , Leo R. Zacharski³

¹Director, Special Hematology and Coagulation Laboratory, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas and Uniformed Services University of the Health Sciences, Bethesda, Maryland
²Section Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire and Dartmouth Medical School, Hanover, New Hampshire
³Veterans Administration Medical Center, White River Junction, Vermont and Dartmouth Medical School, Hanover, New Hampshire

Abstract

ABSTRACT

Coagulation activation in human gliomas may have two consequences: (1) activation of systemic coagulation reactions leading to the development of venous thromboembolic disease, and (2) stimulation of tumor growth and invasion. Anticoagulation in patients with gliomas, therefore, may not only prevent thrombosis but also have anticancer activity. Tissue factor and thrombin are appropriate targets for intervention, and several drugs are suitable for testing. Low-molecular-weight heparin and direct thrombin inhibitors are useful for reducing thrombin production and activity, and recombinant tissue factor pathway inhibitor and statins are examples of drugs that target tissue factor directly. This article reviews the implications of coagulation activation in human gliomas and provides a rationale for clinical testing of anticoagulants as part of a treatment strategy for this devastating human cancer.

KEYWORD

Glioma - tissue factor - coagulation - lovastatin - anticoagulants

Volltext

Referenzen

REFERENCES

1 Greenlee R, Hill-Harmon M, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin . 2001; 51 15-36
2 DeAngelis L. Brain tumors. N Engl J Med . 2001; 344 114-123
3 Marras L, Geerts W, Perry J. The risk of venous thromboembolism is increased throughout the course of malignant glioma. Cancer . 2000; 89 640-646
4 Bjorklid E, Storm-Mathisen J, Storm E, Prydz H. Localization of tissue thromboplastin in the human brain. Thromb Haemost . 1997; 37 91-97
5 Hamada K, Kuratsu J, Saitoh Y. Expression of tissue factor in glioma. Brain Tumor Pathol . 1996; 13 115-118
6 Hamada K, Kuratsu J, Saitoh Y. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer . 1996; 77 1877-1883
7 Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T. Tissue factor, osteopontin, α_vβ3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer . 2000; 82 1967-1973
8 Meehan K, Memoli V, Rousseau S, Zacharski L. Presence of components of the coagulation and fibrinolysis pathways in situ in malignant glioma tissue. Blood . 1994; 84(Suppl 1, part 1) 679a-679a Abst
9 Bardos H, Molnar P, Csecsei G, Adany R. Fibrin deposition in primary and metastatic human brain tumors. Blood Coagul Fibrinolysis . 1996; 7 536-548
10 Heesen M, Kemkes-Matthes B, Deinsberger W, Boldt J, Matthes K. Coagulation alterations in patients undergoing elective craniotomy. Surg Neurol . 1997; 47 35-38
11 Fujii Y, Tanaka R, Takeuchi S. Serial changes in hemostasis after intracranial surgery. Neurosurgery . 1994; 35 26-33
12 Sawaya R, Auccarello M, Elkaliny M, Nishiyama H. Postoperative venous thromboembolism and brain tumors: part 1. Clinical profile. J Neurooncol . 1992; 14 119-125
13 Quevedo J, Buckner J, Schmidt J, Dinapoli R, O'Fallon J. Thromboembolism in patients with high-grade glioma. Mayo Clin Proc . 1994; 69 329-332
14 Brandes A, Scelzi E, Salmistraro G. Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur J Cancer . 1997; 33 1592-1596
15 Anderson F, Huang W, Sullivan C, Hochberg F, Hartman L. The continuing risk of venous thromboembolism following operation for glioma: findings from the glioma outcomes project. Thromb Haemost . 2001; Suppl OC902-OC902 Abst
16 Dhami M, Bona R, Calogero J, Hellman R. Venous thromboembolism and high grade gliomas. Thromb Haemost . 1993; 70 393-396
17 Nurmohamed M, van Riel A, Henkens C. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost . 1996; 75 233-238
18 Agnelli G, Piovella F, Buoncristiani P. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med . 1998; 339 80-85
19 Ornstein D, Zacharski L. Treatment of cancer with anticoagulants: rationale in the treatment of melanoma. Int J Hematol . 2001; 73 157-161
20 Kaufmann R, Patt S, Schafberg H. Functional thrombin receptor PAR1 in primary cultures of human glioblastoma cells. Neuroreport . 1998; 9 709-712
21 Ogiichi T, Hirashima Y, Nakamura S. Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation. J Neurooncol . 2000; 46 1-9
22 Valenzuela R, Shainoff J, DiBello P. Immunoelectrophoretic and immunohistochemical characterizations of fibrinogen derivatives in atherosclerotic aortic intimas and vascular prosthesis pseudo-intimas. Am J Pathol . 1992; 141 861-880
23 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe M. Specificity of a monoclonal antibody for the NH₂-terminal region of fibrin. Mol Immunol . 1984; 21 89-94
24 Ruf W, Mueller B. Tissue factor signalling. Thromb Haemost . 1999; 82 175-182
25 Bromberg M, Konigsberg W, Madison J, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA . 1995; 92 8205-8209
26 Fischer E, Riewald M, Huang H-Y. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest . 1999; 104 1213-1221
27 Ruf W, Mueller B. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol . 1996; 3 379-384
28 Abe K, Shoji M, Chen J. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA . 1999; 96 8663-8668
29 Berkman R, Merrill M, Reinhold W. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest . 1993; 91 153-159
30 Jensen R. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol . 1998; 48 189-196
31 Schiff D, DeAngelis L. Therapy of venous thromboembolism in patients with brain metastases. Cancer . 1994; 73 493-498
32 Bona R, Hickey A, Wallace D. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis. Am J Clin Oncol . 2000; 23 71-73
33 Hutten B, Prins M, Gent M. Incidence of recurrent thromboembolism and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved International Normalized Ratio: a retrospective analysis. J Clin Oncol . 2000; 18 3078-3083
34 Ornstein D, Zacharski L. The use of heparin for treating human malignancies. Haemostasis . 1999; 29(Suppl S1) 48-60
35 Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg J. Low-molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med . 1996; 100 269-277
36 Gould M, Dembitzer A, Sanders G, Garber A. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med . 1999; 130 789-799
37 Hettiarachchi R, Smorenburg S, Ginsberg J. Do heparins do more than just treat thrombosis?. <~>The influence of heparins on cancer spread. Thromb Haemost . 1999; 82 947-952
38 Lensing A, Prins M, Davidson B, Hirsh J. Treatment of deep venous thrombosis with low-molecular weight heparins. A meta-analysis. Arch Intern Med . 1995; 1995 601-607
39 Turpie A, Gallus A, Hoek J. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med . 2001; 344 619-625
40 Eriksson B, Ogren M, Agnelli G. The oral direct thrombin inhibitor ximelagatran (pINN, formerly H 376/95) and its subcutaneous form melagatran compared with enoxaparin as thromboprophylaxis after total hip or total knee replacement. Thromb Haemost . 2001; Suppl OC1638-OC1638 Abst
41 Eriksson H, Wahlander K, Gustafsson D. Efficacy and tolerability of the novel, oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), compared with standard therapy for the treatment of acute deep vein thrombosis. Thromb Haemost . 2001; Suppl OC2348-OC2348 Abst
42 Francis C, Davidson D, Berkowitz S. Randomized, double-blind, comparative study of ximelagatran (pINN, formerly 376/95), an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee arthroplasty (TKA). Thromb Haemost . 2001; Suppl OC44-OC44
43 Bergqvist D, Holmdahl L, Solhaug J-H, Eriksson U. Efficacy and safety of subcutaneous melagatran and oral ximelagatran (pINN, formerly H 376/95) as prophylaxis against thromboembolic complications following general abdominal surgery. Thromb Haemost . 2001; Suppl OC1020-OC1020 Abst
44 Ishibashi H, Nakagawa K, Onimaru M. Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor β1, and tissue factor and also cell growth and invasion activities. Cancer Res . 2000; 60 6531-6536
45 Bajaj M, Bajaj S. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost . 1997; 78 471-477
46 Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med . 2000; 28(Suppl) S31-S33
47 Amirkhosravi A, Meyer T, Chang J-Y. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Blood . 2000; 96(Part 1) 565a-565a Abst
48 }Ferro D, Basili S, Pratico D. Vitamin E reduces monocyte tissue factor expression in cirrhotic patients. Blood . 1999; 93 2945-2950
49 Holschermann H, Kohl O, Maus U. Cyclosporin A inhibits monocyte tissue factor activation in cardiac transplant recipients. Circulation . 1997; 96 4232-4238
50 Susen S, Hazzan M, Labalette M. Pentoxifylline prevents upregulation of monocyte tissue factor in renal transplant recipients undergoing post-graft complications. Thromb Haemost . 2000; 84 764-769
51 Amirkhosravi A, Meyer T, Warnes G. Pentoxifylline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor. Thromb Haemost . 1998; 80 598-602
52 Falanga A, Consonni R, Marchetti M. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood . 1998; 92 143-151
53 Koyama T, Hirosawa S. Anticoagulant effects of synthetic retinoids and activated vitamin D3. Semin Thromb Hemost . 1998; 24 217-226
54 Tenno T, Oberg F, Nilsson K, Siegbahn A. Induction of differentiation in U-937 and NB4 cells is associated with inhibition of tissue factor production. Eur J Haematol . 1999; 63 112-119
55 Falanga A, Iacoviello L, Evangelista V. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood . 1995; 86 1072-1081
56 DiSanto A, Napoleone E, Donati M, Lorenzet R. Angiotensin II upregulates tissue factor expression by human monocytes. Thromb Haemost . 2001; Suppl OC215-OC215 Abst
57 Napoleone E, DiSanto A, Donati M, Lorenzet R. Renin-angiotensin blockade downregulates tissue factor expression by human endothelial cells. Thromb Haemost . 2001; Suppl OC62-OC62 Abst
58 Corseaux D, Ollivier V, Fontaine V. Hemostasis imbalance in experimental hypertension. Prevention by zofenopril. Thromb Haemost . 2001; Suppl OC1024-OC1024 Abst
59 Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Intern Med . 2000; 32 164-176
60 Bouterfa H, Sattelmeyer V, Czub S. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res . 2000; 20 2761-2772
61 Feleszko W, Balkowiec E, Sieberth E. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer . 1999; 81 560-567
62 Kikuchi T, Nagata Y, Abe T. In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells. J Neurooncol . 1997; 34 233-239
63 Macaulay R, Wang W, Dimitroulakos J, Becker L, Yeger H. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro. J Neurooncol . 1999; 42 1-11
64 Ray J, Mamdani M, Tsuyuki R. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med . 2001; 161 1405-1410
65 Rosenson R, Tangney C. Antiatherothrombotic properties of statins. JAMA . 1998; 279 1643-1650
66 Musial J, Undas A, Dreger B, Brozek J, Szczeklik A. Treatment with simvastatin and low-dose aspirin lowers thrombin generation and C-reactive protein (CRP) in patients with ischemic heart disease (IHD) and borderline-high cholesterol levels. Thromb Haemost . 1999; Suppl 728-728 Abst
67 Colli S, Lalli M, Eligini S. Vastatins inhibit tissue factor expression by human macrophages. Thromb Haemost . 1997; Suppl 199-199 Abst
68 Allessandri C, Ferro D, Basilim S. Simvastatin reduces enhanced monocyte tissue factor expression in patients with type IIa hypercholesterolemia. Thromb Haemost . 1997; Suppl 206-206 Abst
69 Soma M, Baetta R, Renzis M D. In vivo enhanced antitumor activity of carmustine [N,N′-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. Cancer Res . 1995; 55 597-602
70 Prasanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem . 1996; 66 710-716
71 Ornstein D, Dixon P, McGlasson D. Lovastatin inhibits tissue factor expression by cultured human melanoma cells- a possible explanation for antineoplastic activity. Thromb Haemost . 2001; Suppl P566-P566 Abst
72 Thibault A, Samid D, Tompkins A. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res . 1996; 2 483-491
73 Larner J, Jane J, Laws E. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol (CCT) . 1998; 21 579-583
74 Splichal J, Ornstein D, Hong-Dice Y, Downs J, Fischer J. Lovastatin for the prevention of melanoma: analysis of AFCAPS/TexCAPS. Proc Am Soc Clin Oncol . 2001; 20 351a-351a Abst
75 Ornstein D, Zacharski L, Memoli V. Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues. Cancer . 1991; 68 1061-1067
76 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe M. Specificity of a monoclonal antibody for the NH2-terminal fragments derived from fibrinogen and fibrin. Mol Immunol . 1983; 20 1191-2000